News

Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.
Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...
Bristol Myers tops revenue expectations on strength of older drugs, shares fall
Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion
Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...
BioPharma Dive3d
Bain leads $300M investment in startup built on Bristol Myers immune drugs
Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...
PE Hub2h
Accel-KKR, Carlyle, Vistria target home care software; Bain Capital, Bristol Myers Squibb launch autoimmune biopharma biz
Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...
Fierce Pharma1d
Bristol Myers touts commercial execution, reckons with recent clinical setbacks
Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...
Bristol Myers, Bain Capital form a new biopharmaceutical company
Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...